TB-500
Phase 2Small molecule
TB-500 is one of 18 small molecule programs targeting Cardiovascular. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Cardiovascular
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Ozempic
Novo NordiskApproved
Plavix
SanofiApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Farxiga
AstraZenecaPhase 3
Letairis
GileadPhase 3
Cialis
Eli LillyPhase 3
Metformin XR
AstraZenecaPhase 3
Xarelto
WWim Janssens
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TB-500. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHudson Biotech